Nektar Therapeutics Stock Price, News & Analysis

Nektar Therapeutics (NASDAQ:NKTR) announced a webcast conference call on November 11, 2020, at 4:15 p.m. EST featuring oncology experts and company management. The event coincides with the 2020 Society for Immunotherapy of Cancer Annual Meeting. Key topics include clinical data from three studies, notably the PIVOT-02 study involving bempegaldesleukin (NKTR-214) and nivolumab. Notable presenters include Drs. Adi Diab, Brendan Curti, and Nina Shah. Interested parties can access the call via dial-in or live audio webcast, with a replay available for two weeks.

Nektar Therapeutics (NKTR) reported Q3 2020 financial results showing revenue growth to $30.0 million from $29.2 million in Q3 2019, and a year-to-date revenue of $129.5 million, up from $80.8 million in the same period last year, driven by milestone payments from Bristol-Myers Squibb for new trials. Operating costs rose to $133.1 million, resulting in a net loss of $108.6 million or $0.61 per share. The company is advancing its immuno-oncology pipeline despite challenges, with promising enrollment in key studies.

Nektar Therapeutics (NASDAQ:NKTR) presented additional clinical data from the Phase 1b study of NKTR-358, a T regulatory cell stimulator, at the ACR 2020 conference. The data showed NKTR-358 was safe and well-tolerated in patients with mild-to-moderate systemic lupus erythematosus (SLE), demonstrating a dose-dependent expansion of regulatory T cells and a reduction in clinical scores after three treatment cycles. The company is advancing to a Phase 2 trial in lupus patients, supported by encouraging biomarker changes, and is pursuing other studies in atopic dermatitis and psoriasis.

Nektar Therapeutics (NASDAQ: NKTR) will host a webcast conference call on November 4, 2020, at 4:15 p.m. EST, featuring insights on NKTR-358, their investigational therapy for autoimmune diseases, during the ACR 2020 event. Dr. David Klatzmann from Sorbonne University will discuss findings from their Phase 1b study. Additional details include a virtual poster presentation on November 9, 2020, showcasing data on regulatory T cells and NKTR-358's role in lupus treatment. A Phase 2 study for NKTR-358 is currently in progress.

Nektar Therapeutics (NKTR) will report its Q3 2020 financial results on November 5, 2020, after U.S. markets close. CEO Howard Robin will lead a conference call at 5:00 p.m. ET. The conference call details include the dial-in number: (877) 881-2183 for U.S. participants and (970) 315-0453 for international callers, with a conference ID of 5192707. The call will be accessible via a live webcast and available for replay until December 1, 2020. For more information, visit their website.

Nektar Therapeutics (NASDAQ: NKTR) has received FDA clearance for an Investigational New Drug application for bempegaldesleukin (BEMPEG, NKTR-214) in a Phase 1b study targeting mild COVID-19. The trial, starting in November, will assess BEMPEG's ability to enhance lymphocyte production, potentially improving treatment outcomes for COVID-19 patients. Key endpoints include changes in lymphocyte counts and clinical progression based on the WHO scale. The study aims to confirm BEMPEG's safety and tolerability while exploring its role in stimulating adaptive immune responses against COVID-19.

Vaccibody AS and Nektar Therapeutics (NKTR) have commenced a Phase 1/2a trial combining bempegaldesleukin (bempeg) with VB10.NEO, a personalized cancer vaccine, for advanced squamous cell carcinoma of the head and neck. The first patient has been dosed in this innovative study aimed at enhancing T cell responses to target tumors. Prior data indicated that VB10.NEO elicited responses in 50% of patients with various solid tumors, leading to optimism about combining it with bempeg. This collaboration aims to deepen the anti-tumor activity by leveraging both therapies' strengths.

Nektar Therapeutics (NKTR) reported Q2 2020 revenue of $48.8 million, significantly up from $23.3 million in Q2 2019, driven by a milestone payment of $25 million from Bristol-Myers Squibb. Cash and investments stood at $1.2 billion, down from $1.6 billion at year-end 2019 due to debt repayment. The net loss for Q2 was $80 million, or $0.45 per share, improving from a loss of $110.3 million in Q2 2019. The company has 5 ongoing registrational trials, with positive developments in immunotherapy and ongoing patient enrollment for NKTR-358 in lupus patients.

Nektar Therapeutics (Nasdaq: NKTR) will announce its second quarter 2020 financial results on August 6, 2020, post-market. CEO Howard Robin will lead a conference call at 5:00 PM ET to discuss the results. Interested parties can access the press release and a live audio-only webcast on Nektar's website. The replay of the call will be available until September 1, 2020. Nektar Therapeutics specializes in biopharmaceuticals, focusing on oncology and immunology.